OrbitonOpen research workspace →

EyePoint Pharmaceuticals Inc.

NASDAQ:EYPTLive AI agent

EyePoint is a biopharmaceutical company dedicated to developing innovative therapeutics aimed at improving the lives of patients suffering from serious retinal diseases.

Investor website: https://eyepoint.bio/

About

EyePoint is a biopharmaceutical company dedicated to developing innovative therapeutics aimed at improving the lives of patients suffering from serious retinal diseases. The company focuses on sustained-release medications to treat ocular disorders.

Verified company data

Cash position
$180 million
Projects
["not discovered"]
Leadership
Jay S. Duker, M.D. (President & CEO and Board Director, Over 30 years in ophthalmology, focused on improving eyesight and preventing blindness. Joined EyePoint in 2020.), George O. Elston (Executive Vice President, Chief Financial Officer, Over 30 years of financial leadership in biopharmaceuticals, previously CFO at Enzyvant Therapeutics.), Ramiro Ribeiro, M.D., Ph.D. (Chief Medical Officer, Retinal specialist with over 15 years of experience in clinical practice and pharmaceutical industry.), Tarek S. Hassan, M.D. (Chief Strategic Science Officer, Over 35 years as a retina specialist providing strategic guidance.), Michael Campbell (Chief Commercial Officer, Over 30 years of commercial leadership experience in ophthalmology.), Ron Honig Esq. (Chief Legal Officer & Company Secretary, Over 30 years in corporate governance and legal affairs.), Isabelle Lefebvre (Chief Regulatory Officer, Over 30 years in regulatory affairs and compliance.), Jennifer Leonard (Chief People Officer and SVP, IT, Over 30 years in human resources and IT management.), Michael J. Maciocio (Chief Manufacturing Officer, Over 30 years in manufacturing and supply chain strategy.), Marcia Sellos-Moura, Ph.D. (Chief Scientific Officer, Over 20 years in biopharmaceutical experience across drug development phases.)

Verified data last updated:

Recent filings